HDAC2 binds HDAC2 Inhibitors

Stable Identifier
R-HSA-9679787
Type
Reaction [binding]
Species
Homo sapiens
Compartment
Locations in the PathwayBrowser
General
SVG |   | PPTX  | SBGN
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout

To carry out gene expression, a cell must control the winding and unwinding of DNA around histones. This is mediated by histone acetyl transferases (HATs) and histone deacetylases (HDACs). HDAC inhibitors inhibit the proliferation of tumour cells by inducing cell cycle arrest, differentiation and/or apoptosis (Zhang et al. 2019). Belinostat (Marks et al. 2000, O'Connor et al. 2015), vorinostat (Marks & Breslow 2007) and romidepsin (Ueda et al. 1994, VanderMolen et al. 2011) are HDAC inhibitors approved for the treatment of Peripheral T-cell lymphomas (PTCLs) (Hood & Shah 2016).

Human papillomaviruses (HPVs) cause epithelial proliferative diseases. The HDAC inhibitors vorinostat, belinostat and panobinostat have been shown to inhibit HPV DNA amplification and cause apoptosis in preclinical experiments (Banerjee et al. 2018).

Literature References
PubMed ID Title Journal Year
7513682 FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

Ueda, H, Nakajima, H, Hori, Y, Fujita, T, Nishimura, M, Goto, T, Okuhara, M

J. Antibiot. 1994
17211407 Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

Marks, PA, Breslow, R

Nat. Biotechnol. 2007
21587264 Romidepsin (Istodax, NSC 630176, FR901228, FK228, depsipeptide): a natural product recently approved for cutaneous T-cell lymphoma

VanderMolen, KM, McCulloch, W, Pearce, CJ, Oberlies, NH

J. Antibiot. 2011
10922406 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells

Marks, PA, Richon, VM, Rifkind, RA

J. Natl. Cancer Inst. 2000
26101246 Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

O'Connor, OA, Horwitz, S, Masszi, T, Van Hoof, A, Brown, P, Doorduijn, J, Hess, G, Jurczak, W, Knoblauch, P, Chawla, S, Bhat, G, Choi, MR, Walewski, J, Savage, K, Foss, F, Allen, LF, Shustov, A

J. Clin. Oncol. 2015
Participants
Participant Of
Authored
Reviewed
Created
Cite Us!